The FDA has approved the first in a new class of migraine drugs that will help fight migraine headaches.
Erenumab (Aimovig) is the first of four new migraine drugs in the pipeline that target migraines.
The drug's manufacturer, Amgen, said the list price will be $575 a month or $6,900 annually. Costs to patients may vary depending on insurance.
For more information, click here.
(Photo: Getty Images)
Jack and Carolyn talked about it on the air. Listen here: